BC Week In Review | May 30, 2016
Clinical News

CG100: Completed Phase II enrollment

Therabron completed enrollment of 88 pre-term infants between 24-29 weeks of gestational age who received positive pressure mechanical ventilation in a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial evaluating 2 single doses of intratracheal CG100....
BC Week In Review | May 25, 2015
Clinical News

CG100 regulatory update

The European Commission granted Orphan Drug designation to CG100 from Therabron to prevent bronchopulmonary dysplasia (BPD). The recombinant human club cell 10kD protein (rhCC10) is in Phase II testing to prevent neonatal BPD. It has...
Items per page:
1 - 2 of 2